FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891958511> ?p ?o ?g. }

• W2891958511 endingPage "98" @default.
• W2891958511 startingPage "90" @default.
• W2891958511 abstract "Avadomide is a novel, small-molecule therapeutic agent that modulates cereblon E3 ligase activity and exhibits potent antitumor and immunomodulatory activities. This first-in-human phase I study (NCT01421524) evaluated the safety and clinical activity of avadomide in patients with advanced solid tumors, non-Hodgkin lymphoma (NHL), and multiple myeloma.Thirty-four patients were treated with avadomide in 7 dose-escalation cohorts using a 3 + 3 design (0.5-3.5 mg, 28-day continuous dosing cycles). The primary objectives were to determine the dose-limiting toxicity (DLT), nontolerated dose (NTD), maximum tolerated dose (MTD), recommended phase II dose, and pharmacokinetics of avadomide. The secondary objective was to determine preliminary avadomide efficacy. Exploratory objectives included evaluation of pharmacodynamic effects of avadomide.DLTs were reported in 2 patients, and grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 14 patients (41%). The most common TEAEs (≥15%) were fatigue, neutropenia, and diarrhea. The NTD and MTD were 3.5 and 3.0 mg, respectively. Of 5 patients with NHL, 1 achieved a complete response, and 2 had partial responses. Although no objective responses were observed in patients with solid tumors, 5 of 6 patients with brain cancer experienced nonprogression of ≥6 months. A dose-dependent relationship between Aiolos degradation in peripheral B and T cells occurred within 5 hours of the first dose of avadomide administered, starting at 0.5 mg.Avadomide monotherapy demonstrated acceptable safety and favorable pharmacokinetics in patients with solid tumors, NHL, and multiple myeloma. In addition, 3 objective responses were observed in NHL." @default.
• W2891958511 created "2018-09-27" @default.
• W2891958511 creator A5001258905 @default.
• W2891958511 creator A5014267088 @default.
• W2891958511 creator A5018125274 @default.
• W2891958511 creator A5022467575 @default.
• W2891958511 creator A5025619970 @default.
• W2891958511 creator A5043395223 @default.
• W2891958511 creator A5047069710 @default.
• W2891958511 creator A5072971421 @default.
• W2891958511 creator A5073134832 @default.
• W2891958511 creator A5075285660 @default.
• W2891958511 creator A5076017612 @default.
• W2891958511 date "2019-01-01" @default.
• W2891958511 modified "2023-10-14" @default.
• W2891958511 title "A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies" @default.
• W2891958511 cites W1628369270 @default.
• W2891958511 cites W1774902545 @default.
• W2891958511 cites W179710673 @default.
• W2891958511 cites W1940514332 @default.
• W2891958511 cites W1970510435 @default.
• W2891958511 cites W1973999018 @default.
• W2891958511 cites W1997952190 @default.
• W2891958511 cites W2001355942 @default.
• W2891958511 cites W2003524270 @default.
• W2891958511 cites W2019607817 @default.
• W2891958511 cites W2044436186 @default.
• W2891958511 cites W2054383376 @default.
• W2891958511 cites W2077848703 @default.
• W2891958511 cites W2086373053 @default.
• W2891958511 cites W2099799689 @default.
• W2891958511 cites W2112757377 @default.
• W2891958511 cites W2125477622 @default.
• W2891958511 cites W2133201432 @default.
• W2891958511 cites W2162643152 @default.
• W2891958511 cites W2257367636 @default.
• W2891958511 cites W2297842386 @default.
• W2891958511 cites W2979397746 @default.
• W2891958511 cites W2979681124 @default.
• W2891958511 cites W2979816844 @default.
• W2891958511 cites W2980311272 @default.
• W2891958511 doi "https://doi.org/10.1158/1078-0432.ccr-18-1203" @default.
• W2891958511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30201761" @default.
• W2891958511 hasPublicationYear "2019" @default.
• W2891958511 type Work @default.
• W2891958511 sameAs 2891958511 @default.
• W2891958511 citedByCount "71" @default.
• W2891958511 countsByYear W28919585112019 @default.
• W2891958511 countsByYear W28919585112020 @default.
• W2891958511 countsByYear W28919585112021 @default.
• W2891958511 countsByYear W28919585112022 @default.
• W2891958511 countsByYear W28919585112023 @default.
• W2891958511 crossrefType "journal-article" @default.
• W2891958511 hasAuthorship W2891958511A5001258905 @default.
• W2891958511 hasAuthorship W2891958511A5014267088 @default.
• W2891958511 hasAuthorship W2891958511A5018125274 @default.
• W2891958511 hasAuthorship W2891958511A5022467575 @default.
• W2891958511 hasAuthorship W2891958511A5025619970 @default.
• W2891958511 hasAuthorship W2891958511A5043395223 @default.
• W2891958511 hasAuthorship W2891958511A5047069710 @default.
• W2891958511 hasAuthorship W2891958511A5072971421 @default.
• W2891958511 hasAuthorship W2891958511A5073134832 @default.
• W2891958511 hasAuthorship W2891958511A5075285660 @default.
• W2891958511 hasAuthorship W2891958511A5076017612 @default.
• W2891958511 hasBestOaLocation W28919585112 @default.
• W2891958511 hasConcept C111113717 @default.
• W2891958511 hasConcept C112705442 @default.
• W2891958511 hasConcept C121608353 @default.
• W2891958511 hasConcept C126322002 @default.
• W2891958511 hasConcept C143998085 @default.
• W2891958511 hasConcept C197934379 @default.
• W2891958511 hasConcept C22979827 @default.
• W2891958511 hasConcept C2776364478 @default.
• W2891958511 hasConcept C2777063308 @default.
• W2891958511 hasConcept C2777288759 @default.
• W2891958511 hasConcept C2778496288 @default.
• W2891958511 hasConcept C2779338263 @default.
• W2891958511 hasConcept C29730261 @default.
• W2891958511 hasConcept C71924100 @default.
• W2891958511 hasConcept C90924648 @default.
• W2891958511 hasConcept C98274493 @default.
• W2891958511 hasConceptScore W2891958511C111113717 @default.
• W2891958511 hasConceptScore W2891958511C112705442 @default.
• W2891958511 hasConceptScore W2891958511C121608353 @default.
• W2891958511 hasConceptScore W2891958511C126322002 @default.
• W2891958511 hasConceptScore W2891958511C143998085 @default.
• W2891958511 hasConceptScore W2891958511C197934379 @default.
• W2891958511 hasConceptScore W2891958511C22979827 @default.
• W2891958511 hasConceptScore W2891958511C2776364478 @default.
• W2891958511 hasConceptScore W2891958511C2777063308 @default.
• W2891958511 hasConceptScore W2891958511C2777288759 @default.
• W2891958511 hasConceptScore W2891958511C2778496288 @default.
• W2891958511 hasConceptScore W2891958511C2779338263 @default.
• W2891958511 hasConceptScore W2891958511C29730261 @default.
• W2891958511 hasConceptScore W2891958511C71924100 @default.
• W2891958511 hasConceptScore W2891958511C90924648 @default.
• W2891958511 hasConceptScore W2891958511C98274493 @default.
• W2891958511 hasFunder F4320309086 @default.

• next